ABSTRACT
Objective To evaluate the efficacy and toxicity of the combination of oxaliplatin and S-1 in the treatment of patients with advanced breast cancer.Methods A total of 72 patients with advanced breast cancer after the treatment failuer of anthracycline and taxane were treated with oxaliplatin and S-1.The first day,they were given oxaliplatin,135 mg/m2,with the 5％ glucose injection 500 ml,the time of intravenous drip should be more than 2 hours.And the S-1 was taken after breakfast and dinner,the dose was 40-60 mg,and the time of duration was 2 weeks,then they had 7 days to rest.The cycle was 21 days.Every 2 cycles,we estimated the efficacy.Patients who were effective and stable kept that chemotherapy regimens,the maximum duration was 6 cycles.The efficacy and toxicities were evaluated after cycles of chemotherapy.Results Two cases (2.8％) had complete response (CR),26 cases (36.1％) had partial response (PR).The response rate (RR) was 38.9％ and the disease control rate (DCR) was 69.4％.The median progress free survival (PFS) was 7.7 months and the median overall survival (OS) was 12.3 months.Subgroup analysis showed that the OS of patients who belong to stage Ⅳ,had two or more metastases or with failure treatment after being treated with anthracycline and taxane was notably shorter than the patients who belong to stage Ⅲ C,only one metastasis,with effective treatment after being treated with anthracycline and taxane,and the differences were statistically significant (10.5 months vs.15.0 months,x2 =4.469,P =0.035;9.3 months vs.15.0 months,x2 =8.297,P=0.004;10.0 months vs.14.0 months,x2 =4.077,P=0.043).The main side effects were neutropenia (19.4％),nausea (8.3％) and nerve toxicity (2.8％),mainly 3-4 degree,and could be welltolerated.The others were diarrhea,impaired liver function,stomatitis,anemia and hand-foot syndrome,mainly 1-2 degree.Conclusion Oxaliplatin combined with S-1 is effective and tolerable in treatment of patients with advanced breast cancer,the adverse reactions can be tolerated.
ABSTRACT
Objective To observe clinical efficacy and safety on the treatment of moderate-severe cancer pain by Fluvoxamine combined with Oxycodone. Methods 120 cancer patients with moderate pain and 120 cases with severe pain were selected, randomly divided into experimental group and control group. The control group were given oxycodone alone , and experimental group given fluvoxamine combined with oxycodone , till the pain relieved, then the degree of pain relief, oxycodone dosage, life quality and side effects were evaluated. Results The degree of pain relief in experimental group were much better than control group (P < 0.05). Oxycodone consumption were lower in experimental group than control group , and the difference was no significant difference in controlling moderate pain (P = 0.065), while statistically significant in controlling severe pain (P = 0.035). The general status, daily activity, mood, and sleep affected by cancer pain were released after treatment, especially in experimental group (P < 0.05). The most common side effects were approximative, and the incidence of constipation, nausea/vomiting, lethargy were lower in experimental group than control group (P =0.026). Conclusion Fluvoxamine combined with Oxycodone can effectively control moderate-severe cancer pain, and reduce the oxycodone dosage and some side effects, and therefore, improve the quality of life.
ABSTRACT
Objective To explore the effect of electronic antiemetic acupuncture in combination with palonosetron in preven‐ting tardive vomiting induced by highly emetogenic chemotherapy for cancer patients .Methods One hundred and twenty cancer pa‐tients undergoing highly emetogenic chemotherapy were divided into observation group and control group(n=60) .The observation group was treated with electronic antiemetic acupuncture in combination with palonosetron and the control group was treated with palonosetron .The different effects against nausea and vomiting between these two groups were evaluated after 24 hours of the chemotherapy .Results Response rate of improvement of nausea for the observation group and control group from the 2nd day to the 8th day were 90 .0% vs 71 .7% ,68 .3% vs 41 .7% ,60 .0% vs 36 .7% ,65 .0% vs 40 .0% ,80 .0% vs 58 .3% ,91 .7% vs 81 .7% , 98 .3% vs 96 .6% .From the 2nd day to the 6th day there were statistical difference of the two groups(P0 .05) .Response rate of prevention of vomit for the observation group and control group from the 2nd day to the 6th day were 98 .3% vs 88 .3% , 81 .7% vs 65 .0% ,75 .0% vs 51 .7% ,90 .0% vs 70 .0% ,98 .3% vs 88 .3% ,and there were statistical difference of the two groups (P<0 .05) .The prevention of vomiting in the 7th day and 8th day of the two groups were 98 .3% vs 86 .7% ,98 .3% vs 88 .3% , there were also statistical difference(P<0 .05) .Conclusion The treatment of electronic antiemetic acupuncture in combination with palonosetron have greater effect in prevention of tardive vomiting than palonosetron caused by highly emetogenic chemotherapy .It can be used conventionally in the chemotherapy .
ABSTRACT
Objective To explore the effect of percutaneous transhepatic gastric variceal embolization joint partial splenic embolization on hemodynamic of portal vein.Methods 54 cases who were clinically diagnosed as cirrhosis with portal hypertension,do the treatment percutaneous transhepatic gastric variceal embolization combined with partial splenic embolization.The preoperative and postoperative free portal vein pressure(FPP) were measured by portal vein intubation,and the preoperative and postoperative portal vein(PV),spleen vein(SV) in hemodynamic changes were compared between color dopplar ultrasound and CT scan scanning.Results Free portal vein pressure were significantly increased after percutaneous transhepatic gastric variceal embolization [(37.05 ± 4.27) cm H2O vs (42.60 ± 5.04)cm H2 O,P ＜ 0.01],and reduced through continuing to partial splenic embolization.In the end there were no statistically significant differences (P ＞ 0.05).After 3 months portal venous blood flow and inner diameter and blood flow velocity only is a little change,but spleen vein inner diameter,blood flow velocity and blood flow were decreased significantly(P ＜ 0.01).Conclusion Only percutaneous coronary arteriovenous embolization can increase portal vein pressure,but which joint partial splenic embolization does not affect the thange of portal venous blood flow dynamics.